Fairvalue-Calculator Fairvalue-Calculator
EN DE

Inhibikase Therapeutics, Inc (IKT) Fair Value & Analysis

Healthcare · US · Market cap $242M

Price$1.87
Fair Value$1.30
Upside-30.5%
Quality95/100
Evidence: Low Range $0.8600 – $1.63

Fair value as of: Jun 25, 2026

Analysis

Inhibikase Therapeutics, Inc (IKT) currently trades at $1.87, while our model-based Fair Value estimate is $1.30 — implying the stock looks roughly 30.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular r…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Inhibikase Therapeutics, Inc (IKT) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.30 versus a price of $1.87 — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IKT?
Our 21-model fair value for Inhibikase Therapeutics, Inc is $1.30 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.87.
What is the quality score of IKT?
Inhibikase Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.